The Parabolic 7 Cracks: What the Chip Sector's Worst Day in Six Years Is Really Telling Investors

The semiconductor sector's worst day in six years reveals deeper concerns about valuation extremes and supply dynamics in the AI chip trade.

SpaceX's $75 Billion IPO Is Rewriting the Rules - Except the Ones That Matter Most

There is a number that captures the audacity of the SpaceX IPO better than any roadshow slide: 555,555,555. That is how many shares Elon Musk's rocket company plans to sell at exactly $135 apiece - a fixed price, not a range - to raise $75 billion in what

A Big Commercial Partner Just Backed This Small-Cap Cancer Company - and the Catalysts Keep Coming

Alpha Tau’s Tolmar partnership adds capital, commercial muscle, and fresh validation for Alpha DaRT. With prostate, pancreatic, skin-cancer, and glioblastoma catalysts advancing, the small-cap oncology story is gaining momentum.

Broadcom's Record Quarter and the 12% Selloff: What the Market Is Really Saying About AI Chips

Broadcom posted record revenue and guidance that would have seemed like science fiction two years ago. Then the stock fell 12% in after-hours trading. Welcome to the AI chip market in 2026, where extraordinary is no longer enough.

Greg Abel Has Launched: What Berkshire's $6.8 Billion Housing Bet Tells Us About the Post-Buffett Era

Greg Abel's first major acquisition as Berkshire CEO signals a more active approach to capital deployment and integration, marking the official beginning of the post-Buffett era.

Alphabet's $80 Billion Bet: When Google Goes to the Market to Win the AI Arms Race

Alphabet announced an $80 billion equity raise to fund AI infrastructure buildout, signaling its commitment to win the AI arms race. The deal includes a $10 billion Berkshire Hathaway investment and a $40 billion at-the-market offering program.

Everyone's Talking About Peptides. One Under-the-Radar Company Is Actually Building the Future of Them

Peptides are everywhere - but Entera Bio is aiming beyond the hype: turning proven injectable therapies into oral tablets, with EB613 headed toward Phase 3 as a potential first-in-class bone-building pill for osteoporosis.

INNIO's $20 Billion IPO: How a GE Spinoff Became the Unlikely Power Broker of the AI Era

There is a number that tells the whole story of INNIO Holding's upcoming IPO better than any roadshow slide deck: 85. That is roughly how many times over the company's annual orders from data center customers have multiplied in just two years. In 2023, INNIO booked

Oil's Worst Month Since COVID: What the US-Iran Ceasefire Deal Means for Energy Markets

There is a number that energy traders have been watching with a mixture of relief and disbelief: 19. That is roughly how much Brent crude oil fell in percentage terms during May 2026 - its worst monthly performance since the COVID-19 pandemic sent demand off a cliff in 2020. The

Dell's 757% AI Server Surge: What the Biggest Hardware Beat in Years Tells Us About the Infrastructure Race

Dell Technologies reported a stunning 757% year-over-year surge in AI server revenue for Q1 FY2027, sending its stock up 32.76% and signaling that the AI infrastructure buildout is accelerating faster than Wall Street models predicted.

Drone Procurement Enters New Capital Cycle as Counter-UAS Market Projected to Reach $20 Billion By 2030

The Trump administration is reportedly in talks to fund U.S. drone manufacturers through the Pentagon's Office of Strategic Capital - a vehicle set for an approximately 1,247% funding increase in fiscal 2027 - while Section 1709 of the FY25 NDAA reshapes the domestic drone supply chain through the

The $1.75 Trillion Bet: What the SpaceX IPO Means for Markets, Investors, and the Future of Capital

There is a number that capital markets have never seen before: $75 billion. That is how much SpaceX is targeting to raise in its initial public offering, set to begin its roadshow on June 4 and price as early as June 11, with Nasdaq trading under the ticker SPCX expected